{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-100714","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2024-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.658872+00:00","generated_at":"2026-05-31T04:18:37.044668+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"United Therapeutics files new cross-claims in FDA suit challenging YUTREPIA NDA acceptance","bullets":["On Sept. 16, 2024, United Therapeutics filed new cross-claims against FDA in the existing FDA Suit.","Cross-claims re-assert challenge to FDA's acceptance of Liquidia's NDA for YUTREPIA (treprostinil).","Liquidia states it will vigorously defend its ability to launch YUTREPIA and against the allegations.","United had voluntarily dismissed a similar challenge on Aug. 20, 2024, before refiling as cross-claims.","Liquidia's prior suit challenging FDA's 3-year NCI exclusivity for Tyvaso DPI remains ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-100714","json":"https://secwatch.observer/filing/0001104659-24-100714.json","markdown":"https://secwatch.observer/filing/0001104659-24-100714.md","text":"https://secwatch.observer/filing/0001104659-24-100714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924100714/0001104659-24-100714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924100714/tm2424262d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:18:37.044668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}